A5017564686- Cervical Cancer and HPV Research
- Global Cancer Incidence and Screening
- Colorectal Cancer Screening and Detection
- Hepatitis Viruses Studies and Epidemiology
- Vector-Borne Animal Diseases
- Animal Disease Management and Epidemiology
- Vaccine Coverage and Hesitancy
- Hepatitis B Virus Studies
Ministry of Health
2021-2024
Background: Cervical cancer is the leading cause of mortality in Kenya, with an estimated 3,200 deaths 2020.Kenya has implemented cervical interventions for more than a decade.We describe evolution programme over last 20 years and assess its performance. Methods:We searched Ministry Health's archives website screening policy documents assessed them using seven items: situational analysis, objectives, key result areas, implementation framework, resource considerations, monitoring evaluation...
Sub-Saharan Africa has the highest rate of cervical cancer cases and deaths worldwide. Kenya introduced a quadrivalent HPV vaccine (GARDASIL, hereafter referred to as GARDASIL-4) for ten-year-old girls in late 2019 with donor support from Gavi, Vaccine Alliance. As may soon graduate Gavi support, it is important evaluate potential cost-effectiveness budget impact current vaccine, alternatives. We used proportionate outcomes static cohort model annual lifetime vaccinating over period...
Cervical cancer is the leading cause of deaths among women in Kenya. In context Global strategy to accelerate elimination cervical as a public health problem, Kenya currently implementing screening and treatment scale-up. For effectively tracking scale-up, baseline assessment service availability readiness was conducted 25 priority counties. We describe findings this efforts
Background Globally, cervical cancer is a major public health problem, with about 604,000 new cases and over 340,000 deaths in 2020. In Kenya, it the leading cause of deaths, 3,000 women dying 2020 alone. Both Kenyan screening guidelines World Health Organization’s Global Cervical Cancer Elimination Strategy recommend human papillomavirus (HPV) testing as primary test. However, HPV not widely available healthcare system Kenya. We conducted pilot study using point care (POC) test to inform...
Abstract Background and Aim Breast cancer is the leading in terms of incidence Kenya. We conducted a breast awareness screening pilot to assess feasibility rolling out national program Methods Conducted Nyeri County during October–November 2019, had three phases; creation, (clinical examination and/or imaging) final evaluation (post‐screening exit interviews retrospective data review). Descriptive statistics on awareness, process outputs were derived. Results During pilot, 1813 CBE, 217...
Background: Sub-Saharan Africa has the highest rate of cervical cancer cases and deaths worldwide. Kenya introduced a quadrivalent HPV vaccine (GARDASIL-4©) for ten-year-old girls in late 2019 with donor support from Gavi, Vaccine Alliance (Gavi). As may soon graduate Gavi support, it is important to evaluate potential budget impact cost-effectiveness this available alternatives. Methods: We used UNIVAC decision model (static proportionate outcomes model) introducing vaccination Kenyan over...